secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2024-02-12T23:59:59+00:00
Accession:  0001193125-24-031008
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics pauses Phase 3 enrollment in epetraborole trial after efficacy concern
--------------------------------------------------------------------------------

- Voluntary pause of Phase 3 enrollment in EBO-301 trial for treatment-refractory MAC lung disease.
- Blinded aggregate analysis showed potentially lower than expected efficacy; no safety concerns cited.
- Phase 2 part completed enrollment with 80 patients; Phase 3 had enrolled nearly 100 patients to date.
- Enrolled patients allowed to continue; topline Phase 2 data expected summer 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312524031008/0001193125-24-031008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312524031008/d744326d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-031008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer